77 results about "Prognostic prediction" patented technology

The present invention relates to an image-based computer-aided prognosis (CAP) system and method that seeks to replicate the prognostic power of molecular assays in histopathology and pathological processes, including but not limited to cancer. Using only a tissue slide samples, a mechanism for digital slide scanning, and a computer, the present invention relates to an image-based CAP system and method which aims to overcome many of the drawbacks associated with prognostic molecular assays (e.g. Oncotype DX) including the high cost associated with the assay, limited laboratory facilities with specialized equipment, and length of time between biopsy and prognostic prediction.

The invention relates to an auxiliary assessment method for prognosis of nasopharynx cancer based on enhanced MRI radiomics. The auxiliary assessment method comprises the steps of: (1), performing MRIimage processing; (2), extracting imaging features; (3), screening the imaging features; (4), establishing a radiomics scoring formula; (5), screening clinical risk factors; and (6), establishing a prognostic survival model: establishing a prognostic observation model through combination of a radiomics score and the clinical risk factors of a patient with nasopharynx cancer, performing qualitative and quantitative prediction on the PFS (progression free survival) of the patient, and furthermore, assessing the performance of the prognostic survival model. The auxiliary assessment method in theinvention has little harm to the image examination of the patient; qualitative and quantitative analysis on the survival time of a specific patient is carried out; therefore, a doctor is assisted tomake an individualized treatment and follow-up visit scheme; furthermore, the doctor is assisted to assess the survival and recurrence time of the patient; simultaneously, the performance of the obtained prognostic survival model is verified; and thus, the accuracy of a prognostic prediction model is ensured.

The invention provides a duodenal adenocarcinoma patient postoperative prognostic prediction system based on a COX proportional hazard model. The system comprises a memory, an information processing module and a prediction result displayer. The information processing module is configured for performing the following calculation and comparing the calculation result with the duodenal adenocarcinomapostoperative prognostic prediction index pre-stored in the memory and outputting the prediction result to the prediction result displayer: (I) the score of each risk factor is calculated according tothe following relation; (II) summation of all the scores obtained in the (I) is performed and the total score Z is calculated; and (III) the three-year survival rate (Y3) or the five-year survival rate (Y5) of the patient is calculated according to the following relation.

The present invention is related to the use of 5-hydroxymethylcytosine or a biomolecule having general structure of 5-hydroxymethycytosine as a biomarker for the detection, treatment monitoring, and prognostic prediction of cancer.

The invention discloses application of a cancer suppressor gene FBXW7 in preparation of drugs used for preventing or treating breast tumors, an expression vector and a diagnosis medicine, belonging to the field of medical biotechnology. Specifically, the invention provides application of the cancer suppressor gene FBXW7 in preparation of drugs used for preventing or treating breast tumors, the expression vector constructed from the gene FBXW7 and a vector pcDNA3.1 and a preparation method thereof, and the breast tumor diagnosis medicine at least including a pair of primers capable of specific amplification of the gene FBXW7 and composed of an upstream primer and a downstream primer. Expression of the cancer suppressor gene FBXW7 is closely related to breast cancer molecular subtyping; the cancer suppressor gene FBXW7 has specific low expression in a breast cancer with high grade malignancy and exerts an inhibitory effect on growth of breast cancer cells. Thus, screening of breast cancers with low expression of the gene has significant meaning to prognostic prediction of the breast cancers; and specific recovery of expression of the cancer suppressor gene in breast cancer cells provides a novel approach for targeted individualized treatment of the breast cancers.

The invention belongs to the field of genetic engineering and in particular relates to an application of a bile exosome long and non-coding RNA (lncRNA) ENST00000588480.1 in diagnosis of bile duct carcinoma, prognostic prediction and target spot drug treatment, wherein the long and non-coding RNA is positively correlated with TNM staging and poor prognosis of a patient.

The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Galectin-1 used as a tumor screening marker or a tumor progression marker for colorectal cancer. Galectin-3 used as a tumor screening marker. Galectin-4 used as a tumor progression marker, a tumor screening marker, or a prognostic prediction marker for colorectal cancer. A method of analyzing the galectin concentration in a collected blood sample using the galectin. A colorectal cancer marker detection kit comprising a detection antibody selected from the group consisting of a fluorescently labeled galectin-1 antibody, a fluorescently labeled galectin-3 antibody, and a fluorescently labeled galectin-4 antibody.

The invention relates to the technical field of breast cancer diagnosis, and specifically discloses RNA (Ribonucleic Acid) circEPSTI1 (Epithelial-stromal Interaction 1) and application thereof in triple negative breast cancer. The application of the RNA circEPSTI1 in the triple negative breast cancer comprises the following steps: firstly, collecting a to-be-detected suspected triple negative breast cancer tissue sample, extracting total RNA, specifically and reversely transcribing the cyclic RNA circEPSTI1 (hsa_circRNA_000479) into cDNA (Complementary Deoxyribonucleic Acid) by using the total RNA as a template; carrying out real-time quantitative PCR (Polymerase Chain Reaction) amplification by using a specific PCR primer; using beta-actin as a reference gene, thus obtaining a relative quantitative deltaCT value of circEPSTI1; reminding that the circEPSTI1 is in positive expression when deltaCT is smaller than or equal to 5.52. According to the RNA circEPSTI1 and the application thereof in the triple negative breast cancer, disclosed by the invention, the RNA circEPSTI1 is applied to prognostic prediction of a triple negative breast cancer patient through relatively and quantitatively detecting the expression situation of the circEPSTI1 in the suspected triple negative breast cancer tissue sample.

This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder.

The present invention provides a detecting method of detecting malignant cells in a patient's specimen or a biological sample. Specifically, the inventive method includes the steps of extracting a genomic DNA, digesting said genomic DNA with one or multiple methylation sensitive restriction enzymes, and amplifying by PCR with one or multiple selected primers. The PCR can be performed in a conventional or a real-time platform. The inventive method can detect leukemia cells in 90% ALL patients at a sensitivity of up to 10⁻⁶. The inventive method also provides broad clinical applications in cancer (including hematopoietic and solid tumors) screening and risk assessment, early detection and diagnosis confirmation, and therapeutic monitoring, minimal residual disease detection and prognostic prediction.

The invention discloses a reagent for auxiliarily diagnosing lung cancer lymph node metastasis, comprising 8 antibodies which are used for detecting 8 protein markers which are MMP1 (matrix metalloproteinase-1), TIMP1 (tissue inhibitor of metalloproteinases metallopeptidase inhibitor 1), IQGAP1 (IQ motif containing GTPase activating protein 1), TPX2 (targeting protein for Xklp2), uPA (Urokinase-type plasminogen activator), Cathepsin-D, Fascin and pIgR/SC (polymeric immunoglobulin receptor/secretory component). By adopting the 8 antibodies and an immunohistochemical staining result, lung cancer lymph node metastasis can be auxiliarily diagnosed, and the reagent is expected to be used for the risk estimation of lung squamous cell cancer lymph node metastasis and the prognostic prediction. The reagent has high creditability, strong practicability and clinical use value based on the clinical routine immunohistochemical staining technology when the reagent is used for auxiliary diagnosis.

The invention discloses a function-driven multi-molecular marker for individualized prediction of colorectal cancer prognosis and a device and an evaluation method thereof. Prognostic predictive markers are simultaneously screened from multiple cancer large sample data sets of multiple centers, and predictive effects of the multi-molecular marker are validated and comprehensively evaluated in three independent data sets. The application of the above methods and strategies ensures the reliability of the multi-molecular marker in judgment of the prognosis of a colorectal cancer patient; the multi-molecular marker combination is not affected by the batch effect of an experiment or the difference of a detection platform, thereby ensuring the stability of the multi-molecular marker in the judgment of the prognosis of the colorectal cancer patient; the multi-molecular marker combination does not need to be subjected to data standardization between multiple samples before use, thereby facilitating the use and ensuring the clinical operability of the multi-molecular marker in the judgment of the prognosis of the colorectal cancer patient.

The invention relates to a kit for detecting peripheral blood miRNA variation of lung cancer, and particularly relates to a kit and a use method thereof. The kit comprises the following components: a specific primer, a specific probe, a U6snRNA primer and a fluorescence PCR reaction liquid. The detection method comprises the following steps: collecting a peripheral blood sample of a patient and extracting total RNA in the blood; carrying out real-time quantitative PCR by the kit, so that expression quantities of hsa-miR-10b-5p and hsa-miR-141-3p are rapidly detected in large scales; and comparing with internal reference U6snRNA, thus realizing prognostic prediction on a lung cancer patient. The kit is easy and rapid to operate, good in repeatability, strong in specificity, and high in sensitivity.

The invention discloses an application of a long-chain non-coding RNA (ribonucleic acid) gene LOC553103. The gene LOC553103 is used for preparing a preparation for monitoring recurrence, metastasis and prognostic prediction of gastric carcinoma. The expression level of the gene LOC553103 in gastric carcinoma tissue has a positive correlation with recurrence and metastasis of gastric carcinoma; a serial number of the gene in NCBI (National Center of Biotechnology Information) is NR-110997. The survival time of a patient with high expression of LOC553103 is shorter, and accordingly, LOC553103 can be taken as a prediction molecular marker for recurrence and metastasis of gastric carcinoma. According to the application, a powerful tool for molecular biology is provided for auxiliary diagnosis and prognostic prediction of gastric carcinoma, and the gene LOC553103 has profound clinical significance and great popularization and application prospects.

The invention discloses a method of noninvasively detecting bladder cancer. The method can provide early screening of bladder cancer, estimate the risk of a subject to experience bladder cancer, and provide typing of bladder cancer and/or prognostic prediction, so that diagnostic sensitivity, specificity and accuracy are improved; noninvasive, convenient, efficient and rapid diagnosis of bladder cancer is achieved. The invention also provides a bladder cancer diagnosis system, as well as a method of detecting methylation level of a target gene in urine.

The invention discloses endometrioid adenocarcinoma prognosis-related gene and protein as well as an application thereof. The invention provides a kit a to assist grouping of patients population with endometrioid adenocarcinoma, comprising a substance for detecting mRNA level expression of 21 genes: PRC1, NUSAP1, MCM6, PIWIL2, TYMS, CCNB2, ESM1, BUB1, BARD1, MCM7, CDK6, PCNA, NDC80, CCNE2, RFC4, CCNE1, SERPINA1, FOS, DUSP1, CCL20, and NR4A1. The experiment found a gene model and a protein marker capable of performing prognostic prediction of disease-free survival time of endometrioid adenocarcinoma. The model has important clinical meaning for reflecting biological characteristics of endometrioid adenocarcinoma and prognostic prediction.

The invention discloses a noninvasive detection method of bladder cancer. The noninvasive detection method of bladder cancer can realize early screening of bladder cancer, risk assessment about the fact that a subject suffers from bladder cancer, and parting and/or prognostic prediction of bladder cancer, the sensitivity, specificity and accuracy of diagnosis are improved, and the effect of noninvasive, convenient and rapid, efficient and rapid diagnosis of bladder cancer is realized. The invention further provides a bladder cancer diagnosis system, a reagent combination for detecting the methylation level of a target gene in urine, and a method for detecting the methylation level of the target gene in the urine.

The invention discloses an extranodal nasal NK/T cell lymphoma prognostic marker, an application thereof, a prognostic prediction model and a construction method thereof. The prognostic marker is remarkably related to disease staging and Ki67 positive rate, and the prognostic marker is CD20; it is found for the first time that the infiltration density of CD20 positive cells in the extranodal nasalNK/T cell lymphoma tumor tissue is positively correlated with the survival time of a patient, and is negatively correlated with the disease staging of the patient; it shows that CD20 can be used as aprediction index for good prognosis of the patient; the prognostic marker CD20 can make up for the deficiency of good prognostic prediction indexes in the ENKTCL field; the construction method of theprognosis prediction model is simple; the density of CD20 positive cells in a tumor tissue slice of the patient is detected by combining an immunohistochemical method with a slice microscanning technology and the like, so that a patient prognosis prediction model is constructed; and the patient prognosis prediction model has great significance in guiding individualized treatment of clinical extranodal nasal NK/T cell lymphoma.

The invention discloses the application of long-chain non-coding RNA LINC00336 serving as a biomarker to the preparation of a lung adenocarcinoma prognostic detection preparation. The expression levelof the long-chain non-coding RNA LINC00336 in a patient suffering from lung adenocarcinoma can be detected, a powerful molecular biology base is provided for prognostic prediction of the patient suffering from lung adenocarcinoma, and profound clinical significance and generalization performance are achieved.